Nerve Growth Factor in Alcohol Use Disorders

Flavio Maria Ceci¹,†, Giampiero Ferraguti¹,†, Carla Petrella², Antonio Greco³, Massimo Ralli³, Angela Iannitelli⁴, Valentina Carito², Paola Tirassa², George N. Chaldakov⁵, Marisa Patrizia Messina⁶, Mauro Ceccanti⁷ and Marco Fiore⁷,*

¹Department of Experimental Medicine, Sapienza University Hospital of Rome, Italy; ²Institute of Biochemistry and Cell Biology, National Research Council (IBBC-CNR), Rome, Italy; ³Department of Sense Organs, Sapienza University Hospital of Rome, Italy; ⁴Department of Biotechnology and Applied Clinical Sciences, University of L’Aquila, Italy; ⁵Department of Anatomy and Cell Biology, Medical University, Varna, Bulgaria; ⁶Department of Gynecology, Obstetric, and Urology, Sapienza University of Rome, Italy; ⁷Centro Riferimento Alcologico Regionale Lazio, Sapienza University of Rome, Italy

Abstract: The nerve growth factor (NGF) belongs to the family of neurotrophic factors. Initially discovered as a signaling molecule involved in the survival, protection, differentiation, and proliferation of sympathetic and peripheral sensory neurons, it also participates in the regulation of the immune system and endocrine system. NGF biological activity is due to the binding of two classes of receptors: the tropomyosin-related kinase A (TrkA) and the low-affinity NGF pan-neurotrophin receptor p75. Alcohol Use Disorders (AUD) are one of the most frequent mental disorders in developed countries, characterized by heavy drinking, despite the negative effects of alcohol on brain development and cognitive functions that cause individual’s work, medical, legal, educational, and social life problems. In addition, alcohol consumption during pregnancy disrupts the development of the fetal brain causing a wide range of neurobehavioral outcomes collectively known as fetal alcohol spectrum disorders (FASD). The rationale of this review is to describe crucial findings on the role of NGF in humans and animals, when exposed to prenatal, chronic alcohol consumption, and on binge drinking.

Keywords: NGF, alcohol use disorders, binge drinking, chronic alcohol consumption, addiction, fetal alcohol spectrum disorders.

1. INTRODUCTION

Alcohol use disorders (AUD) are a plethora of diseases due to alcohol dependence and loss of control over alcohol consumption. Alcohol use disorders induce neuronal and cognitive impairment, which can cause depression, anxiety, suicide, and abuse of other drugs. Starting from NGF for its trophic and protective role and using PubMed and Scopus as the main search engines, the aim of this review is to provide an updated view on the role of NGF in AUD. In particular, this review will focus on recent works regarding chronic alcohol consumption and binge drinking in humans and animals. Moreover, we will take into consideration the Fetal Alcohol Spectrum Disorders (FASD) issue as alcohol exposure during pregnancy causes neuronal death and alters NGF activity.

2. NERVE GROWTH FACTOR - NGF

Neurotrophic factors control cell differentiation, proliferation, growth, migration, survival, metabolism, and apoptosis. Neurotrophins belong to the family of neurotrophic factors and include polypeptide growth factors, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4/5 [2]. NGF, expressed both in the peripheral and central nervous system, is a neurotrophin that regulates the survival and proliferation of neuronal cells [3-5]. It was discovered in the year 1951 by Rita Levi-Montalcini and Victor Hamburger from a sarcoma tissue that released a soluble growth factor which was able to induce overgrowth of fibers from sensory or sympathetic nerve cells placed nearby [6, 7]. NGF is synthesized as a 130 kD precursor, namely proNGF, that is formed by three proteins: α-NGF, β-NGF, and γ-NGF. The third protein is a serine protease that cuts off the β subunit producing the 26 kD mature NGF that is biologically active [4, 8].

2.1. NGF Receptors

NGF exerts its effects by binding two classes of receptors: the tropomyosin-receptor kinase A (TrkA), and the low-affinity NGF receptor p75 (LNGFR/p75⁷⁵NTF) [3, 9, 10]. TrkA belongs to the family receptor of Trk, tyrosine kinases, along with TrkB and TrkC, which regulates synaptic strength and plasticity in the nervous system [11]. The receptor p75 is a low-affinity neurotrophin receptor and a member of the tumor necrosis factor receptor family [12]. The Trk subfamily

*Address correspondence to this author at the Institute of Biochemistry and Cell Biology, National Research Council (IBBC-CNR), c/o Department of Sense Organs, Sapienza University Hospital, Via del Policlinico 162, 00185 Rome, Italy; E-mail: marcofiore.roma@gmail.com
†These Authors contributed equally to this work.
of receptors is composed of immunoglobulin-C2 domains, amino acid repeats full of leucine and cysteine residues in the extracellular domain, and a tyrosine kinase domain with a small cytoplasmic tail. The p75 receptor has four negatively charged cysteine-rich amino acid repeats in the extracellular domain and a single cytoplasmic domain that includes a “death” domain [13]. For the TrkA receptor, only the domain nearest to the cell membrane is needed to bind to its ligand [14, 15]. The binding of NGF to TrkA starts the homodimerization of the receptor and the autophosphorylation of certain tyrosine residues within the intracellular domains. This site of phosphorylation (Fig. 1) then recruits adapter proteins that have src-homology-2 (SH-2) or phosphotyrosine-binding motifs. The adapter proteins, after phosphorylation, start several intracellular signaling cascades involved in cell survival [9, 16]. A pathway activated by the binding between NGF and the receptor TrkA involves the mitogen-activated protein kinase (MAPK). This pathway induces the activation of Ras, a GTPase that phosphorylates the serine/threonine kinase Raf. This latter activates the MAPK cascade, which regulates the activity of several transcription factors, such as the cAMP response element-binding protein (CREB), a transcription factor that translocates in the nucleus to control the expression of anti-apoptotic genes [16, 17]. Although the receptor p75 does not contain a catalytic motif, it interacts with several proteins that regulate neuronal survival and differentiation, as well as synaptic plasticity. The binding of NGF to p75 activates several signaling pathways. The primary signaling pathway activated by p75 is the Jun kinase-signaling cascade. This pathway activates p53, a transcriptional factor that can initiate apoptosis. Furthermore, this cascade can activate apoptosis by increasing the expression of the Fas receptor ligand [18]. Nerve growth factor binding to the receptor p75 also stimulates the activation of NF-KB, thereby promoting neuronal survival [19]. Ligand engagement of p75 has been shown to activate acid sphingomyelinase, which results in the production of ceramide [20]. Ceramide promotes both apoptotic and survival pathways started by p75 ligation [21]. Ceramide is known to regulate many signaling pathways, such as the ERK, Jun kinase, NF-kB signaling pathways as well as the activity of TrkA phosphorylating serine residues [22].

2.2. NGF Functions

Nerve growth factor was initially identified as a signaling molecule involved in growth, survival, and proliferation of

---

**Fig. (1). Binding of NGF to TrkA.** NGF binding to TrkA starts the homodimerization of the receptor and the autophosphorylation of tyrosine residues within the intracellular domains. Phosphorylation allows recruitment of adapter proteins that have src-homology-2 (SH-2) or phosphotyrosine-binding motifs. Adapter proteins, after phosphorylation, start intracellular signaling cascades involved in cell survival. *(A higher resolution / colour version of this figure is available in the electronic copy of the article).*
sympathetic and sensory neurons [4, 23, 24]. It is also involved in the regulation of the immune system and the endocrine system, including the adipo endocrine system [25-27]. Consequently, altered expression of NGF and its receptors are involved in many seemingly unrelated diseases, including neuronal disorders (Alzheimer’s and other neurodegenerative diseases) [17, 28-30], aging [31], cancer physiology [32-35], ocular diseases [36-38], growth and development [33, 34, 39], autoimmune diseases (rheumatic arthritis, multiple sclerosis, and other autoimmune diseases) [40], pregnancy, delivery and postpartum [41], oxidative stress-related diseases [42-48], neuroinflammation caused by parasitic diseases [49-56], and cardiometabolic diseases, such as type 2 diabetes mellitus, obesity and metabolic syndrome [57-63]. Furthermore, pieces of evidence on humans indicate that NGF and its receptors are known to be altered in ethanol-induced toxicity, which is the inducing-cause of brain changes [64, 65] and mental retardation [66-72]. A subtle role played by NGF was also hypothesized for schizophrenia development [73-79], as shown in humans and schizophrenia animal models.

In the peripheral nervous system (PNS) NGF has a central role in the development, maintenance, and regeneration of mammalian sympathetic and sensory neurons [80]. During postnatal life, NGF continues to act as a survival factor for many sympathetic neurons, while sensory neurons become independent of this growth factor in the postnatal period [3]. In the central nervous system (CNS), NGF is produced by neurons and glial cells of the cerebral cortex, of the hippocampus, of the hypothalamus and acts as a protective factor of cholinergic neurons, cells that are involved in the cognitive process, such as learning and memorization [4, 81].

Studies carried out during the last few years found that NGF receptors are expressed in primary (thymus, bursa of Fabricius, bone marrow) and secondary (spleen, tonsils, lymph nodes) lymphoid organs, as well as in some immunocompetent cells, such as thymic epithelial cells and bone marrow stromal cells [82-87]. For this reason, both these tissues and cells are potential targets for NGF. Moreover, it has been described the role of NGF during inflammatory disorders and allergic diseases [88-94].

The fact that NGF is secreted in humans’ bloodstream in response to stress and its’ cellular targets being identified in the endocrine system, suggest that this molecule may regulate physiological homeostasis through neuroendocrine mechanisms [4, 95, 96]. NGF is also involved in the acquisition of male and female reproductive capacity and stimulates the hypothalamic-pituitary-adrenal axis (Fig. 2), increasing the secretion of adrenocorticotropic hormone and corticosteroids [97, 98]. In addition, hormones have been shown to regulate NGF synthesis and release [99]. The exogenous administration of testosterone to female mice increases the synthesis of NGF in the submaxillary salivary glands, whereas castration in males highly reduces NGF in the glands [3].

3. ACETYLCHOLINE AND NGF

NGF plays a key role in regulating the biochemical and morphological phenotype of basal forebrain cholinergic neurons in the fully differentiated central nervous system [100]. Cholinergic neurons are characterized by the presence of choline acetyltransferase (ChAT), the acetylcholine synthesizing enzyme, choline transporter (CHT), and vesicular acetylcholine transporter (VAcHT); ChAT has been identified as the most selective marker of cholinergic cells [101, 102]. In addition to its role as a trophic and survival factor for cholinergic neurons, NGF regulates the expression of CHT, ChAT, and VAcHT [103-105]. Disorders in NGF transport and lower processing of proNGF to mature NGF may be the cause for selective degeneration of cholinergic neurons of the basal forebrain in the brain of patients with Alzheimer’s Disease (AD) [102, 106]. In recent years, attention has been focused on NGF as a potential therapeutic agent for a variety of neurodegenerative disorders [102]. Karami et al., studying the activity of ChAT in the cerebrospinal fluid (CSF) of AD patients with encapsulated cell implants releasing NGF (EC-NGF), found after 12 months following the NGF treatment, an increase in ChAT and acetylcholinesterase activity in the CSF. Moreover, CSF ChAT activity showed a high correlation with patient’s performance in the cognitive test during treatment with EC-NGF. These patients remained stable in cognition long after the removal of the EC-NGF implants [102].

4. ALCOHOL USE DISORDERS

Alcohol use disorders (AUD) are the most frequent and untreated mental disorders in developed countries and the American Medical Association defines it as a chronic and relapsing disease [107, 108]. Nearly 2 billion people in the world consume alcohol, with 76.3 million who have diagnosable alcohol use disorders [109]. According to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) diagnostic criteria, in 2012-13, 36% of males and 22.7% of females adults in the USA met the criteria for alcohol use disorders at some time in their lives [110, 111]. The probability of developing alcohol use disorders raises with the frequency of binge drinking, even though most heavy drinkers do not show the criteria for alcohol dependence [112].

Alcohol abuse is associated with many different diseases. Alcohol use has been attributed to both negative and positive effects. While cardiovascular protection might be gained from very low doses, binge drinking is linked with high mortality [113, 114]. The primary causes of death that depend on alcohol consumption are injury, alcoholic liver disease, heart diseases, stroke, cancer, and gastrointestinal diseases [115]. Ethanol is the intoxicating agent in alcoholic drinks that leads to abuse and dependence [116]. The risk of damage increases steeply when more than 10-20 g of alcohol is consumed in a day. The transition from episodic drinking to binge drinking increases the risk of accidents, injuries, violence, and heart diseases [117].

Alcohol influences a large number of neurotransmitters in the brain that are involved in cognition, emotion, and motivation [118]. Rewarding, anxiolytic, and social facilitating effects are due to low doses of alcohol consumption. As the dose increases, alcohol causes cognitive and psychomotor disruptions that increase the risks of injury [119]. Alcohol crosses the blood-brain barrier and widely alters neuronal...
functions, including phospholipid membranes, ion channels and receptors, synaptic and network functions, and intracellular signaling molecules [120]. Alcohol interacts with many neurotransmitters: it directly increases GABA, glycine, nicotinic, acetylcholine and serotonin activity; it indirectly increases dopamine, opioid, and endocannabinoid activity and inhibits glutamate transmission (Fig. 3). These complex effects cause acute intoxication [121].

Alcohol use disorders do not depend only on the person’s moral choices, but are a result of the combined effects of many personal, social, and biological factors [119]. Cultures that promote abuse in alcohol drinking as a lifestyle are responsible for the increase in AUD cases in the population [122]. Also, early initiation to alcohol consumption in adolescence is a factor that could be responsible for developing AUD in adulthood [123]. More risk factors include a family history of alcohol dependence, low parental control and little family support, childhood attitude and mood disorders, low self-control, and positive association between alcohol consumption and social outcomes [124]. Twin studies have estimated that 50-70% of the risk of developing alcohol use disorders depends on genetic factors [125]. The most studied genetic correlation is with genes that reduce the risk. The liver enzymes that metabolize alcohol are alcohol dehydrogenase and the mitochondrial form of aldehyde dehydrogenase (ALDH2) [119]. People with a single copy of the allele ALDH*2 have defective alcohol metabolism and drinking alcohol causes facial flushing, sweating, tachycardia, nausea, vomiting, and headache. These reactions protect against developing alcohol use disorders [126]. To date, alleles found to be associated with alcohol dependence cause a low increase in the risk of developing alcohol use disorders [127]. These alleles alter dopaminergic, opioidergic, GABAergic, serotonergic, cholinergic, and glutamatergic neurotransmission [128].

According to DSM-5, the diagnosis of alcohol use disorders requires at least two of eleven symptoms. Three methods based on structured and short questionnaires, such as the Alcohol Use Disorders Identification Test (AUDIT), the brief version AUDIT-C, and CAGE, can identify patients who need further assessment [129-131]. The physical examination evaluates the symptoms due to intoxication and withdrawal. The signs of intoxication are slurred speech, ataxia, and inappropriate affect. Instead, the first signs of alcohol withdrawal are restlessness, tachycardia, and fine action tremor. Alcohol values are measured in the blood or in the breath [119]. Standard blood tests, liver tests, and the biomarker γ-glutamyl transpeptidase (γGT) are frequently aberrant in patients with alcohol use disorders, but these investigations alone are of little value because of poor sensitivity and specificity [132, 133]. Many other biomarkers for alcohol use disorders diagnosis are more sensitive and specific, but they are not widespread due to their high cost and limited availability. These biomarkers comprehend carbohydrate-deficient transferrin, ethyl glucuronide, ethyl sulphate, phosphatidyl ethanol, and fatty acid ethyl esters [133-135].
NGF and Alcohol

5. NGF AND CHRONIC ALCOHOL CONSUMPTION IN HUMANS

NGF is a neurotrophic factor involved in the growth and differentiation of nerve cells and in the prevention of damage to mature neurons. NGF is also known for its beneficial effect on recovery from cognitive deficits after brain damage [136-138]. In addition, it could play an important role in protecting neurons from cytotoxic damage induced by ethanol [139-141]. Several studies have been conducted in alcohol-dependent patients to determine the correlation between plasma NGF concentration and alcohol dependence. The next morning after admission to the Hangang Sacred Heart Hospital, Lee et al. interviewed and sampled forty-one male patients with alcohol dependence and compared them with forty-one healthy male subjects. Lee et al. found that the plasma NGF concentration was elevated in AUD patients within 24h of abstinence [142]. In the study of Kohler et al., fifteen patients with a diagnosis of alcoholism according to the DSM-IV criteria and fifteen healthy subjects participated consecutively in a two weeks withdrawal study. Alcohol dependent subjects showed, after the acute withdrawal over two weeks of alcohol abstinence, lower NGF levels when compared to the healthy patients. In particular, mean NGF concentrations increased initially and then decreased significantly from days three to fourteen [143]. These findings are in agreement with the epigenetic down-regulation of the NGF gene during alcohol withdrawal [144]. It is known that increased methylation of CpG-sites in the gene promoter reduces mRNA expression of the interested gene [145]. Heberlein investigated the correlations between alterations in NGF serum concentrations and changes in the methylation of the NGF promoter during alcohol withdrawal. Fifty-seven patients with alcohol dependence showed a significant decrease in the NGF serum levels from day seven up to day fourteen of alcohol withdrawal, and a significant increase in methylation of the CpG-sites within the NGF gene promoter. These results suggest epigenetic regulation of NGF gene expression during alcohol withdrawal [144]. Alterations in proinflammatory cytokines have been associated with affective disorders, which play an important role in alcohol consumption [146, 147]. Recently, in alcohol dependence patients undergoing withdrawal, Heberlein and colleagues found a linear association between the methylation of CpG-sites within the NGF gene promoter and IL-6 serum levels [148]. In a study conducted on young patients with alcohol use disorders, Lhullier et al. found higher serum levels of NGF when compared to control [149]. Taken together, these results show that NGF plasma concentration increases during intoxication to protect against the toxic effects of alcohol [150], but then decreases during the abstinence period. Nevertheless, the number of studies is not sufficient for consistent results.

Patients with alcohol dependence show a decline in their cognitive functions even after they quit consuming alcohol [151]. Other studies investigated the relationship between NGF plasma concentration and the decline in cognitive function of alcohol-dependent patients during the abstinence period. The trail-making test B, a test that includes motor components and visual scanning, showed an important correlation with the NGF plasma concentration. The NGF levels were higher in patients with lower trail-making test B score, indicating faster performance speed and a higher executive function. This finding may suggest a protective role of NGF in preventing neuronal damage in patients with alcohol dependence [152].

Another investigation demonstrated that withdrawal from chronic consumption of either ethanol or heroin caused a significant increase in plasma NGF, suggesting that the re-
sulting anxiety condition may trigger the NGF release [153]. Quite interestingly, no changes were observed in the levels of bloodstream NGF of non-dependent human subjects that used to drink alcoholic beverages (mean age 41 years) 30 min before and 60 min after drinking 1 pint of red wine [153]. Although the functional significance of these phenomena required further investigations, authors hypothesized that the increased levels of circulating NGF might be involved in homeostatic adaptive and/or reparative mechanisms.

5.1. NGF and Chronic Alcohol Consumption in Animals

Dependence and rewards are regulated by complex neuronal circuits where the nucleus accumbens (NAc) plays a crucial role [154-156]. In the NAc, there are projections of neurons that release gamma-aminobutyric acid (GABA), and a small population of interneurons that produce either acetylcholine or GABA and different neuropeptides, like neuropeptide Y (NPY) [157-159]. NPY is a neurotransmitter/neuromodulator implicated in the control of a wide range of physiological functions and behaviors, such as alcohol consumption, withdrawal, and neuronal excitability [160-164]. Pereira et al. studied the effects of chronic consumption and subsequent withdrawal on the expression of NPY, acetylcholine, and on the levels of ChAT in the NAc of abstinent rats that received an intracerebroventricular infusion of NGF [165]. During chronic alcohol consumption, the number of NPY-immunoreactive neurons increased and returned to control values after withdrawal, whereas the density of cholinergic varicosities was reduced by 50% during chronic consumption and by 64% during withdrawal. However, the increase in the number of NPY-immunoreactive neurons, the increase in the density of cholinergic varicosities and enlargement of cholinergic interneurons after exogenous administration of NGF, suggests that withdrawal changes might be mediated by the withdrawal-induced disruption of NGF trophic support [165, 166]. Even in the hippocampal formation, the cholinergic neurons and the GABAergic interneurons expressing NPY are vulnerable to the effects of chronic alcohol intake and abstinence [167-175]. More recently, Pereira et al. studied the effects of chronic alcohol consumption and subsequent withdrawal in the dentate gyrus, a hippocampus region containing a large population of NPY-immunoreactive neurons and cholinergic innervation [158, 159, 176]. In this study, they show that NPY expression in the hilus of the dentate gyrus increased after withdrawal and turned back to control values after NGF intracerebroventricular infusion [177]. The levels of VACHT were found to be reduced by 24% in chronic alcohol consumption rats and by 46% in withdrawn rats, but after the administration of NGF to withdrawn rats, the expression of VACHT increased to values above control levels [177]. These findings are in agreement with previous studies showing that exogenous NGF protects the phenotype and prevents withdrawal-induced degeneration of the basal forebrain cholinergic neurons.

5.2. NGF and Binge Drinking in Humans

The World Health Organization (WHO) defines binge drinking as consuming at least 60 g of alcohol in one drinking episode [178]. The National Institute of Alcoholism and Alcohol Abuse (NIAAA) defines binge drinking as a “pattern of drinking that brings alcohol concentration to 0.08 g/dl”, a concentration reached in about two hours after five drinks (70 g of alcohol) for men and after four drinks (56 g of alcohol) for women [179]. These definitions describe binge drinking as episodic and acute alcohol intoxication. Binge drinking is widespread in adolescents and young adults and it causes neurodevelopmental impairments, violence, injuries, family, school and psychiatric problems, and subsequent alcohol dependence [180-182]. Heberlain et al. studied the acute effects of alcohol intoxication in patients suffering from alcohol dependence. In this study, acute alcohol intoxication was related to an increase in NGF plasma levels, which decreased after withdrawal. These results indicate that NGF plasma levels may increase to block the toxic effects of alcohol due to acute intoxication [150].

NGF acts as a soluble mediator for different immune cells and plays a relevant role in the immune response [82]. Moreover, significant evidence indicates that ethanol abuse increases the risk of infection by impairing the ability of monocytes/macrophages to act as antigen-presenting cells and by altering the synthesis and release of cytokines [183-186]. To investigate whether or not ethanol has similar effects on NGF synthesis in blood cells as in the neurons of the CNS, Caroleo et al. studied the effects of acute ethanol exposition in blood monocyte-derived macrophages cultured in vitro [187-189]. These cells, isolated from peripheral blood of healthy donors in basal conditions, produce little NGF, which increases if they are activated by treatment with lipopolysaccharide (LPS) in vitro. The acute exposure of LPS-activated cultures to ethanol alters NGF synthesis, reduces the expression of TrkA, and the release of TNF-α levels [189]. Acute ethanol intoxication also induces an increase in IL-10 synthesis, an anti-inflammatory cytokine that decreases the production of proinflammatory cytokines like TNF-α and IL-1 [185].

5.3. NGF and Binge Drinking in Animals

Adolescence represents a period in which a significant refinement of the neurotransmitter system allows the transition of an immature brain to a more mature and efficient adult brain [190]. In particular, during these modifications, cholinergic neurons are subjected to maturational refinement and reinforcement of cholinergic projections [191-193]. Unfortunately, in humans, this period is also identified with a higher frequency of alcohol binge drinking, which causes loss of cholinergic neurons, loss of choline acetyltransferase (ChAT), an increase in NF-kB p65 phosphorylation and an increase in its proinflammatory target genes like TNF-α [194-203]. These last findings suggest that the loss of cholinergic neurons may be due to the activation of neuroimmune signaling as a result of binge drinking [204]. Recently, Vetreno et al. showed that adolescent intermittent ethanol (AIE) treatment, used a model of human adolescent binge drinking, brought to a decrease in ChAT in neurons of the basal forebrain of adult rats and a decrease in high-affinity NGF receptor TrkA and a decrease in low-affinity receptor p75NTR, both used as markers of cholinergic neurons. Additionally, loss of ChAT after AIE treatment was associated with an increase in pNF-kB p65, a neuroimmune marker, in
the basal forebrain of adult rats. These changes are blocked by the anti-inflammatory drug indomethacin, a non-steroidal molecule able to block neuroimmune signaling [204]. Together, these findings indicate that adolescent binge drinking induces neuroimmune signaling, which may cause loss of cholinergic neurons in the adult basal forebrain.

The cholinergic system in the hippocampus has an essential role in spatial cognition and is a target site of EtOH neurotoxicity [205, 206]. Different hypotheses have been used to explain ethanol-induced damage of cholinergic neurons, one of these is the direct toxicity of ethanol or its metabolite acetaldehyde (AcH). To verify this latter hypothesis, Jamal et al. studied the hippocampus the effects of acute ethanol intoxication in Aldh2 knockout (Aldh2-KO) mice that lack the expression of human mitochondrial aldehyde dehydrogenase type 2 (ALDH2) [207]. Acute ethanol intoxication (2 g/kg) caused a decrease in ChAT expression in Aldh2-KO mice, an increase in acetylcholinesterase (AChE) expression, and no modification in the expression of NGF in both Aldh2-KO and WT mice [207]. These findings indicate that a low level of ChAT and a high level of AChE can lead to a reduction in acetylcholine and a consequent decrease in cognitive function. An increase in the expression of NGF with consequent trophic support may only occur after chronic exposition to ethanol.

5.4. NGF and Fetal Alcohol Spectrum Disorders

The discovery of alcohol as a teratogen molecule, in the year 1973, and the finding of long-term effects of prenatal alcohol exposure indicates that consuming alcohol during pregnancy can alter fetal development [208, 209]. The effects of alcohol on fetus sphere from the absence of damage to abortion, including Fetal Alcohol Spectrum Disorders (FASD) such as Fetus alcohol syndrome (FAS), partial FAS (PFAS), associated neonatal congenital defects (Alcohol-Related Birth Defects, ARBD), and neurological development disorders (Alcohol-Related Neurodevelopmental Disorders, ARND) [210, 211]. FAS is the main cause of mental retardation in the world but is also the foremost preventable cause of neurobehavioral and developmental abnormalities [212]. FAS can be suspected in neonatal age by the presence of microcephaly and typical facial dysmorphism [213, 214]; during childhood, beyond the signs already described, psychomotor retardation, behavioral disorders, attention and concentration problems can be detected [214]; during adolescence, in addition to the previous signs behavioral, scholastic and social problems can be added [214]. Even though FASD is a frequent cause of disability, the exact incidence and prevalence of FASD in the world are not clear. This underestimation of the problem leads to an incorrect diagnosis and doesn’t help the possible rehabilitation of many children.

Fig. (4). Schematic representation of the effects of alcohol abuse throughout its metabolites (i.e. acetaldehyde) or reactive oxygen species (ROS) on NGF synthesis/release or TrkA/p75 disproportion leading to neuronal apoptosis or cell death in other target tissues of ethanol intoxication (i.e. liver). (A higher resolution / colour version of this figure is available in the electronic copy of the article).
with mental retardation [214]. Paternal alcohol consumption may also induce changes in the newborns, as shown in humans and in animal models [215, 216].

Alcohol consumption during pregnancy induces neuronal cell death in the offspring by altering the synthesis and uptake of NGF and the distribution of its receptors [217-219]. In rodents, chronic alcohol consumption reduces NGF levels in the hippocampus and reduces the ChAT activity in the septum, hippocampus, and cortex [220]. Similar results were obtained when an acute administration of ethanol, to pregnant rats, was sufficient to change the physiological levels of NGF in the hippocampus and the localization of p75 in the septum of the offspring [188]. Alcohol consumption during pregnancy can also damage the proliferation and differentiation of neurons leading to deficits in the limbic area, responsible for cognitive activity [221, 222]. In the entorhinal cortex, a region of the hippocampal formation, the exposition of pregnant mice to ethanol during mouse fetal life causes neuroanatomical and neurofunctional alterations during neurogenesis of the entorhinal cortex. These morphological modifications are associated with altered levels of NGF in the entorhinal cortex of prenatal alcohol-treated mice [223]. NGF changes in the mouse brain limbic system were also disclosed following paternal alcohol consumption [2, 216].

Other growth factors may regulate the survival, differentiation, and maintenance of cellular phenotype [3, 224, 225]. NGF, hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) are the main growth factors controlling the physiopathology of the brain, liver, kidney, and are altered in mice exposed to ethanol early [2, 48, 218, 226]. In aged mice, the exposition to ethanol during fetal life and lactation affects these growth factors: NGF was higher in the frontal cortex and hippocampus, HGF was increased in the hippocampus and frontal cortex, and VEGF was elevated in the frontal cortex and in the hippocampus and lower in liver [227].

During pregnancy, maternal alcohol consumption can indirectly disrupt fetal development by altering the function and interactions of maternal and fetal hormones [228]. NGF plays a crucial role in the development, maintenance, and functions of the endocrine system [4, 229, 230]. Ceccanti et al. showed that early administration of ethanol and wine during mouse fetal life causes long-lasting changes in the thyroid, testis, and adrenal glands of aged mice. In particular, high levels of NGF were observed in the thyroid and testis of aged mice when exposed only to ethanol, while in the adrenal glands, high levels of NGF were observed when they are exposed to both ethanol and red wine [231].

CONCLUSION

The role of NGF withdrawal by TrkA/p75 imbalance in nerve cell apoptosis has been debated [232]. Chronic/binge/prenatal alcohol throughout the induced oxidative stress or by direct action of its metabolites (i.e. acetaldehyde), may disrupt NGF synthesis or release or create a disproportion between TrkA and p75 (Fig. 4) leading to neuronal apoptosis or cell death in other target tissues of ethanol intoxication (i.e. liver). The NGF and other growth factors may then be considered crucial elements for disclosing innovative information on AUD. In particular, important findings show increased NGF plasma concentrations during alcohol intoxication and a protective role against neuronal degeneration. The future course of action will help to understand these mechanisms in developing new therapeutic strategies, based on NGF trophic and protective achievements.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Authors thank Sapienza University of Rome and IBBC-CNR for supporting this work.

REFERENCES

[1] Barde, Y.A. Neurotrophic factors: an evolutionary perspective. J. Neurobiol., 1994, 25(11), 1329-1333. http://dx.doi.org/10.1002/neu.480251102 PMID: 7852988
[2] Carito, V.; Ceccanti, M.; Ferraguti, G.; Coccurello, R.; Ciafrè, S.; Tirassa, P.; Fiore, M. NGF and BDNF alterations by prenatal alcohol exposure. Curr. Neuropharmacol., 2019, 17(4), 308-317. http://dx.doi.org/10.2174/1570159X1566617082510108 PMID: 28847297
[3] Levi-Montalcini, R. The nerve growth factor 35 years later. Science (80-.), 1987, 237(4819), 1154-1162.
[4] Fiore, M.; Chaldakov, G.N.; Aloe, L. Nerve growth factor as a signaling molecule for nerve cells and also for the neuroendocrine-immune systems. Rev. Neurosci., 2009, 20(2), 133-145. http://dx.doi.org/10.1515/REVNEURO.2009.20.2.133 PMID: 19774790
[5] Ebendal, T. NGF in CNS: experimental data and clinical implications. Prog. Growth Factor Res., 1989, 1(2), 143-159. http://dx.doi.org/10.1016/0955-2235(89)90008-2 PMID: 2562358
[6] Levi-Montalcini, R.; Hamburger, V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool., 1951, 116(2), 321-361. http://dx.doi.org/10.1002/jez.1401160206 PMID: 14824426
[7] Meakin, S.O.; Shooter, E.M. The nerve growth factor family of receptors. Trends Neurosci., 1992, 15(9), 323-331. http://dx.doi.org/10.1016/0166-2236(92)90047-C PMID: 1382329
[8] Donovan, M.J.; Miranda, R.C.; Kraemer, R.; McCaffrey, T.A.; Tessarollo, L.; Mahadeo, D.; Sharif, S.; Kaplan, D.R.; Tsoufas, P.; Parada, L. Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am. J. Pathol., 1995, 147(2), 309-324. PMID: 7639328
[9] Kaplan, D.R.; Martin-Zanca, D.; Parada, L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature, 1991, 350(6314), 158-160. http://dx.doi.org/10.1038/350158a0 PMID: 1706478
[10] Chao, M.V. Trophic factors: An evolutionary cul-de-sac or door into higher neuronal function? J. Neurosci. Res., 2000, 59(3), 353-355. http://dx.doi.org/10.1002/(SICI)1097-4547(20000220)59:3<353::AID-JNR3>3.0.CO;2-S PMID: 10679770
[11] Huang, E.J.; Reichardt, L.F. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem., 2003, 72(1), 609-642. http://dx.doi.org/10.1146/annurev.biochem.72.121801.161629 PMID: 12676795
NGF and Alcohol

Current Neuropharmacology. 2021, Vol. 19, No. 1 53

[12] Smith, C.A.; Farrah, T.; Goodwin, R.G. The TNF receptor superfamily of cellular and viral proteins: activation, and cell death. Cell, 1994, 76(6), 959-962. http://dx.doi.org/10.1016/0092-8674(94)90372-7 PMID: 8137429

[13] Yano, H.; Chao, M.V. Neurotrophin receptor structure and interactions. Pharm. Acta Helv., 2000, 74(3), 253-260.

[14] Banfield, M.J.; Naylor, R.L.; Robertson, A.G.S.; Allen, S.J.; Daws, B.; Brady, R.L. Specificity in Trk receptor neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5. Structure, 2001, 9(12), 1191-1199. http://dx.doi.org/10.1016/S0969-2126(01)00681-5 PMID: 11738045

[15] Wiesmann, C.; Ullsch, M.H.; Bass, S.H.; de Vos, A.M. Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor. Nature, 1999, 401(6749), 184-188. http://dx.doi.org/10.1038/43705 PMID: 10433815

[16] MacPhee, I.J.; Barker, P.A. Brain signaling pathway promotes survival, not death, of immunopurified neurotrophin receptor. Science (80-.). 1994 265(5178),1596-9.

[17] DeFreitas, M.F.; McQuillen, P.S.; Shatz, C.J. A novel p75<sup>Trk</sup> neuronal signaling pathway promotes survival, not death, of immunopurified neocortical subplate neurons. J. Neurosci., 2001, 11, 21(14), 5121-9.

[18] MacPhie, I.J.; Barker, P.A. Brain-derived neurotrophic factor binding to the p75<sup>Trk</sup> neurotrophin receptor reduces TrkA signaling while increasing serine phosphorylation in the TrkA intracellular domain. J. Biol. Chem., 1997, 272(38), 23547-23551. http://dx.doi.org/10.1074/jbc.272.38.23547 PMID: 9295291

[19] Fiore, M.; Amendola, T.; Tiraesa, V.; Tirassa, P.; Alleva, A.; Aloe, L. Egy drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. Eur. J. Neurosci., 2007, 25(9), 2473-2480. http://dx.doi.org/10.1111/j.1460-9568.2007.05883.x PMID: 17970722

[20] Chaldakov, G.N.; Fiore, M.; Toncev, A.B.; Aloe, L. Neuroepidemiology: a novel component of neuroendocrinology. Cell Biol. Int., 2010, 34(10), 1051-1053. http://dx.doi.org/10.1002/cbi.201005059 PMID: 20825365

[21] Alleva, E.; Aloe, L.; Bigi, S. An updated role for nerve growth factor in neurobehavioural regulation of adult vertebrates. Rev. Neurosci., 1993, 4(1), 41-62. http://dx.doi.org/10.1515/REVNEURO.1993.4.1.41 PMID: 7952382

[22] Tore, F.; Toncev, A.; Fiore, M.; Tuncel, N.; Attanassova, P.; Aloe, L.; Chaldakov, G. From adipose tissue protein secretion to adipopharmacology of disease. Immunol. Endocr. Metab. Agents Med. Chem., 2007, 7(2), 149-155. http://dx.doi.org/10.2174/187152207780363712

[23] Cifare, S.; Ferraguti, G.; Tirassa, P.; Iannitelli, A.; Ralli, M.; Greco, A.; Chaldakov, G.N.; Rosso, P.; Fico, E.; Messina, M.P.; Carito, V.; Tarani, L.; Ceccanti, M.; Fiore, M. Nerve growth factor in the psychiatric brain. riv. Psychiatr., 2020, 53(1), 4-15. http://dx.doi.org/10.17083/32137323051620 PMID: 32051620

[24] Fiore, M.; Angelucci, F.; Aloe, L.; Iannitelli, A.; Korf, J. Nerve growth factor and brain-derived neurotrophic factor in schizophrenia and depression: Findings in humans, and animal models. Curr. Neuropharmacol., 2005, 1(2), 109-123. http://dx.doi.org/10.2174/15701590347720706

[25] Amendola, T.; Fiore, M.; Aloe, L. Postnatal changes in nerve growth factor and brain derived neurotrophic factor levels in the retina, visual cortex, and geniculate nucleus in rats with retinitis pigmentosa. Neurosci. Lett., 2003, 345(1), 37-40. http://dx.doi.org/10.1016/S0304-3903(03)00491-9 PMID: 12809983

[26] Fiore, M.; Tiraesa, V.; Amendola, T.; Tirassa, P.; Aloe, L. Brain NGF and EGF administration improves passive avoidance response and stimulates brain precursor cells in aged male mice. Physiol. Behav., 2002, 77(2-3), 473-483. http://dx.doi.org/10.1001/0013-9384(2002)00875-2 PMID: 12419420

[27] Cervilla, J.A.; Rivera, M.; Molina, E.; Torres-González, F.; Bellón, J.A.; Moreno, B.; de Dios Luna, J.; Lorente, J.A.; de Diego-Otero, Y.; King, M.; Nazareth, I.; Gutiérrez, B. PREDICT Study Core Group. The 5-HTTLPR s/o genotype at the serotonin transporter gene (SLC6A4) increases the risk for depression in a large cohort of primary care attendees: the PREDICT-gene study. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2006, 141B(8), 912-917. http://dx.doi.org/10.1002/ajmg.b.30455 PMID: 17063469

[28] De Santis, S.; Pace, A.; Bove, L.; Cognetti, F.; Properzi, F.; Fiore, M.; Tiraesa, V.; Savarese, A.; Simone, M.D.; Jandolo, B.; Manzoni, L.; Aloe, L. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin. Cancer Res., 2000, 6(1), 90-95. PMID: 10656436

[29] Aloe, L.; Manni, L.; Properzi, F.; De Santis, S.; Fiore, M. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton. Neurosci., 2000, 86(1-2), 84-93. http://dx.doi.org/10.1016/S1566-0702(00)00247-2 PMID: 11269929

[30] Chaldakov, G.N.; Tuncel, N.; Beltowsk, J.; Fiore, M.; Raneci, G.; Toncev, A.; Panayotov, P.; Zitkova, N.; Hinev, A.; Anakievski, D. Adipoparacrinology: An emerging field in biomedical research. Balkan Med. J., 2012, 29(1), 2-9. http://dx.doi.org/10.5152/balkanmedj.2012.022

[31] Rosso, P.; De Nicolò, S.; Carito, V.; Fiore, M.; Iannitelli, A.; Moreno, S.; Tiraesa, P. Ocular nerve growth factor administration modulates brain-derived neurotrophic factor signaling in prefrontal cortex of healthy and diabetic rats. CNS Neurosci. Ther., 2017, 23(2), 198-208. http://dx.doi.org/10.1111/cns.12661 PMID: 28044424

[32] Tiraesa, P.; Rosso, P.; Iannitelli, A. Ocular nerve growth factor (ngf) and ngf eye drop application as paradigms to investigate ngf neuroprotective and reparative actions. Methods Mol. Biol., 2018, 1727, 19-38. http://dx.doi.org/10.1007/978-1-4939-7571-6_2 PMID: 29222770

[33] Aloe, L.; Skaper, S.D.; Leon, A.; Levi-Montalcini, R. Nerve growth factor and autoimmune diseases. Autoimmunity, 1994, 6(2), 141-150. http://dx.doi.org/10.3109/09695539409000542 PMID: 7772704

[34] D’Angelo, A.; Ceccanti, M.; Petrella, C.; Greco, A.; Tiraesa, P.; Rosso, P.; Ralli, M.; Ferraguti, G.; Fiore, M.; Messina, M.P. Role of neurotrophins in pregnancy, delivery and postpartum. Eur. J. Obstet. Gynecol. Reprod. Biol., 2020, 247, 32-41. http://dx.doi.org/10.1016/j.ejogrb.2020.01.046 PMID: 32058187
NGF and Alcohol

Aloe, L.; Simone, M.D.; Properzi, F. Nerve growth factor: a ne...

Ciriaco, E.; Dall’Aglio, C.; Hannestad, H. Expression of mRNA encoding neurotrophins and neurotrophin receptors in rat thymus, spleen tissue and immunocompetent cells. Regulation of neurotrophin-4 mRNA expression by mitogens and leukotriene B4. Eur. J. Biochem., 1994, 223(3), 733-741.

http://dx.doi.org/10.1001/j.1432-1033.1994.tb19047-5 PMID: 8055949

Aloe, L.; Properzi, F.; Probert, L.; Akassoglou, K.; Kassiotis, G.; Micera, A.; Fiore, M. Learning abilities, NGF and BDNF brain levels in two lines of TNF-α transgenic mice, one characterized by neurological disorders, the other phenotypically normal. Brain Res., 1999, 840(1-2), 125-137.

http://dx.doi.org/10.1016/S0006-8993(99)01748-5 PMID: 10517960

Aloe, L.; Fiore, M.; Probert, L.; Turri, P.; Tirassa, P. Overexpression of tumour necrosis factor alpha in the brain of transgenic mice differentially alters nerve growth factor levels and choline acetyltransferase activity. Cytokine, 1999, 11(1), 45-54.

http://dx.doi.org/10.1016/cyt.1998.0397 PMID: 10080878

Fiore, M.; Probert, L.; Kollias, G.; Akassoglou, K.; Alleva, E.; Stanisz, M. Neurobehavioral alterations in developing transgenic mice expressing TNF-α in the brain. Brain Behav. Immun., 1996, 10(2), 126-138.

http://dx.doi.org/10.1016/brbi.1996.0013 PMID: 811936

Fiore, M.; Angelucci, F.; Alleva, E.; Branchi, I.; Probert, L.; Aloe, L. Learning performances, brain NGF distribution and NPY levels in transgenic mice expressing TNF-alpha. Behav. Brain Res., 2000, 112(1-2), 165-175.

http://dx.doi.org/10.1016/S0166-4382(00)00189-7 PMID: 10862948

Aloe, L.; Fiore, M. TNF-α ex-pressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. Neurosci. Lett., 1997, 238(1-2), 65-68.

http://dx.doi.org/10.1016/S0304-3991(97)00850-1 PMID: 9464656

Otten, U.; März, P.; Reese, K.; Hock, C.; Kunz, D.; Rose-John, S. Cytokines and neurotrophins interact in normal and diseased states. Ann. N. Y. Acad. Sci., 2000, 917(1), 322-330.

http://dx.doi.org/10.1111/j.1749-6630.2000.tb05398.x PMID: 11268339

Fiore, M.; Alleva, E.; Stanisz, A.; Chizzolini, C.; Stanisz, A.J. Nerve growth factor and neuroimmune interactions in inflammatory diseases. Ann. N. Y. Acad. Sci., 2000, 917(1), 268-272.

http://dx.doi.org/10.1111/j.1749-6630.2000.tb05392.x PMID: 11268353

Aloe, L.; Alleva, E.; Fiore, M. Stress and nerve growth factor: findings in animal models and humans. Pharmacol. Biochem. Behav., 2002, 73(1), 159-166.

http://dx.doi.org/10.1016/S0030-4922(01)00757-8 PMID: 12076735

Mannii, L.; Aloe, L.; Fiore, M. Changes in cognition induced by social isolation in the mouse are restored by electro-acupuncture. Physiol. Behav., 2009, 98(5), 537-542.

http://dx.doi.org/10.1016/j.physbeh.2009.08.011 PMID: 19733189

Aloe, L.; Bracci-Laudiero, L.; Alleva, E.; Lambiase, A.; Micera, A.; Tirassa, P. Emotional stress induced by parachute jumping enhances blood nerve growth factor levels and the distribution of nerve growth factor receptors in lymphocytes. Proc. Natl. Acad. Sci. USA, 1994, 91(22), 10440-10444.

http://dx.doi.org/10.1073/pnas.91.22.10440 PMID: 7937971

Cirulli, F.; Alleva, E. The NGF saga: from animal models of psychiatric disorders to human Alzheimer disease. Front. Neuroendocrinol., 2009, 30(3), 379-395.

http://dx.doi.org/10.1016/j.yfrne.2009.05.002 PMID: 19442684

Aloe, L. Adrenoleukodystrophy decreases nerve growth factor in young adult rat hippocampus. Proc. Natl Acad. Sci. USA, 1989, 86(14), 5636-5640.

http://dx.doi.org/10.1073/pnas.86.14.5636 PMID: 2664787

Iulita, M. F.; Cuello, A. C. The NGF metabolic pathway in the CNS and its dysregulation in Down syndrome and Alzheimer’s disease. Curr. Alzheimer Res., 2016, 13, 53-67.
NGF and Alcohol

[131] Dhalla, S.; Kopec, J.A. The CAGE Questionnaire for Alcohol Misuse: A Review of Reliability and Validity Studies; Clinical and Investigative Medicine, 2007, 30.

[132] Bertholet, N.; Winter, M.R.; Cheng, D.M.; Samet, J.H.; Saitz, R. How accurate are blood (or breath) tests for identifying self-reported heavy drinking among people with alcohol dependence? Alcohol. Alcohol., 2014, 49(4), 423-429.

[133] http://dx.doi.org/10.1093/alcalc/agu016 PMID: 24740846

[134] Litten, R.Z.; Bradley, A.M.; Moss, H.B. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol. Clin. Exp. Res., 2010, 34(6), 955-967.

http://dx.doi.org/10.1111/j.1530-0285.2010.01170.x PMID: 20374219

[135] Ferraguti, G.; Colli, P.; Carito, V.; Battagliese, G.; Mancinelli, R.; Ciafre, S.; Tirassa, P.; Criccarelli, R.; Cipriani, A.; Messina, M.P.; Fiore, M.; Ceccanti, M. Ethylglycoluridine in the urine as a marker of alcohol consumption during pregnancy: Comparison with four alcohol screening questionnaires. Toxicol. Lett., 2017, 275, 49-56.

http://dx.doi.org/10.1016/j.toxlet.2017.04.016 PMID: 28430931

[136] Heberlein, A.; Schuster, R.; Kleimann, A.; Groh, A.; Kordon, A.; Opfermann, B.; Lichteningh, R.; Gröschl, M.; Kornhuber, J.; Bleich, S.; Frielingsdorff, H.; Hillelmacher, T. Joint effects of the epigenetic alteration of neurotrophins and cytokine signaling: a possible exploratory model of affective symptoms in alcohol-dependent patients? Alcohol. Alcohol., 2017, 52(3), 277-281.

http://dx.doi.org/10.1093/alcalc/ago100 PMID: 28430931

[137] Heberlein, A.; Moreira, F.P.; da Silva, R.A.; Marques, M.B.; Bittencourt, G.; Pinheiro, R.T.; Souza, L.D.M.; Portela, L.V.; Lara, D.R.; Jansen, K.; Wiener, C.D.; Osip, J. Increased serum neurotrophin levels related to alcohol use disorder in a young population sample. Alcohol. Clin. Exp. Res., 2015, 39(1), 30-33.

http://dx.doi.org/10.1111/acer.12592 PMID: 25623403

[138] Heberlein, A.; Bleich, S.; Bayerlein, K.; Frielingsdorff, H.; Gröschl, M.; Kornhuber, J.; Hillelmacher, T. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 2008, 33(7), 999-1003.

http://dx.doi.org/10.1016/j.psyneuen.2008.05.011 PMID: 18639986

[139] Heberlein, A.; Bleich, S.; Bayerlein, K.; Frielingsdorff, H.; Gröschl, M.; Kornhuber, J.; Hillelmacher, T. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 2008, 33(7), 999-1003.

http://dx.doi.org/10.1016/j.psyneuen.2008.05.011 PMID: 18639986

[140] Heberlein, A.; Bleich, S.; Bayerlein, K.; Frielingsdorff, H.; Gröschl, M.; Kornhuber, J.; Hillelmacher, T. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 2008, 33(7), 999-1003.

http://dx.doi.org/10.1016/j.psyneuen.2008.05.011 PMID: 18639986

[141] Heberlein, A.; Bleich, S.; Bayerlein, K.; Frielingsdorff, H.; Gröschl, M.; Kornhuber, J.; Hillelmacher, T. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 2008, 33(7), 999-1003.

http://dx.doi.org/10.1016/j.psyneuen.2008.05.011 PMID: 18639986

[142] Heberlein, A.; Bleich, S.; Bayerlein, K.; Frielingsdorff, H.; Gröschl, M.; Kornhuber, J.; Hillelmacher, T. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 2008, 33(7), 999-1003.

http://dx.doi.org/10.1016/j.psyneuen.2008.05.011 PMID: 18639986

[143] Heberlein, A.; Bleich, S.; Bayerlein, K.; Frielingsdorff, H.; Gröschl, M.; Kornhuber, J.; Hillelmacher, T. NGF plasma levels increase due to alcohol intoxication and decrease during withdrawal. Psychoneuroendocrinology, 2008, 33(7), 999-1003.

http://dx.doi.org/10.1016/j.psyneuen.2008.05.011 PMID: 18639986

[144] Suzuki, M.M.; Bird, A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet., 2008, 9(6), 465-476.

http://dx.doi.org/10.1038/nrg2341 PMID: 18463664

[145] Schiepers, O.J.G.; Wickers, M.C.; Maes, M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(2), 201-217.

http://dx.doi.org/10.1016/j.pnpbp.2004.11.003 PMID: 15694227

[146] Uhart, M.; Wand, G.S. Stress, alcohol and drug interaction: an update of human research. Addict. Biol., 2009, 14(1), 43-64.

http://dx.doi.org/10.1111/j.1369-1600.2008.00313.x PMID: 18855603

[147] Carlezon, W.A., Jr; Thomas, M.J. Biological substrates of reward and aversion: a nucleus accumbens activity hypothesis. Neuropharmacology, 2009, 56(Suppl. 1), 122-132.

http://dx.doi.org/10.1016/j.neuropharm.2008.06.075 PMID: 18675281

[148] Sesack, S.R.; Grace, A.A. Cortico-Basal Ganglia reward network: microcircuitry. Neuropharmacology, 2010, 59(1), 27-47.

http://dx.doi.org/10.1016/j.neuropharm.2009.09.003 PMID: 19675534

[149] Meredith, G.E. The Synaptic Framework for Chemical Signaling in Nucleus Accumbens. In Annals of the New York Academy of Sciences; 1999.

http://dx.doi.org/10.1111/j.1749-6632.1999.tb09266.x

[150] Baraban, S.C. Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuroporpharmacology, 2004, 38(4), 261-265.

http://dx.doi.org/10.1016/j.neopen.2004.06.006 PMID: 15337378
NGF and Alcohol

http://dx.doi.org/10.1016/j.brainres.2013.09.035 PMID: 24062609

Jones, K.L.; Smith, D.W. Recognition of the fetal alcohol syndrome in early infancy. Lancet, 1973, 302(7836), 999-1001.
http://dx.doi.org/10.1016/S0140-6736(73)91092-1 PMID: 4127281

Matson, S.N.; Bernes, G.A.; Doyle, L.R. Fetal alcohol spectrum disorders: a review of the neuropsychological deficits associated with prenatal alcohol exposure. Alcohol. Clin. Exp. Res., 2019, 43(6), 1046-1062.
http://dx.doi.org/10.1111/acerr.14040 PMID: 30964197

Corlale, G.; Fiorentino, D.; Di Lauro, F.; Marchitelli, R.; Scalese, B.; Fiore, M.; Mavaglia, M.; Ceccanti, M. Fetal Alcohol Spectrum Disorder (FASD): neurobehavioral profile, indications for diagnosis and treatment. Riv. Psichiatri, 2012, 47(3), 359-369.
http://dx.doi.org/10.1018/1356.15062 PMID: 24326748

May, P.A.; Baete, A.; Russo, J.; Elliott, A.J.; Blankenship, J.; Kalberg, W.O.; Buckley, D.; Brooks, M.; Hasken, J.; Abdul-Rahman, O.; Adam, M.P.; Robinson, L.K.; Manning, M.; Hoyne, H.E. Prevalence and characteristics of fetal alcohol spectrum disorders. Pediatrics, 2014, 134(5), 855-866.
http://dx.doi.org/10.1542/peds.2013-3319 PMID: 25349310

Banakar, M.K.; Kudur, N.S.; George, S. Fetal alcohol spectrum disorder (FASD). Indian J. Pediatr., 2009, 76(11), 1173-1175.
http://dx.doi.org/10.1007/s12098-009-0253-9 PMID: 20012971

Cranston, M.E.; Mhanni, A.A.; Marles, S.L.; Chudley, A.E. Concordance of the three methods for palpable tissue length measurement in the assessment of fetal alcohol spectrum disorder. Can. J. Clin. Pharmacol., 2009, 16(1), e234-e241.
PMID: 19372628

Vetreno, R.P.; Patel, Y.; Patel, U.; Walter, T.J.; Crews, F.T. Adolescent interleukin-6 expression in the human alcoholic prefrontal cortex is linked to prenatal alcohol exposure. Addict. Biol., 2016, 21(4), 776-787.
http://dx.doi.org/10.1111/adb.12255 PMID: 25940002

Vetreno, R.P.; Patel, Y.; Patel, U.; Walter, T.J.; Crews, F.T. Adolescent interleukin-6 expression in the human alcoholic prefrontal cortex is linked to prenatal alcohol exposure. Addict. Biol., 2016, 21(4), 776-787.
http://dx.doi.org/10.1111/adb.12255 PMID: 25940002

Sartori, L.; Houriez, R.; Bearzatto, B.; Gall, D.J.; Schiiffmann, S.N.; Cheron, G. Parkinje cell dysfunction and alteration of long-term synaptic plasticity in fetal alcohol syndrome. Proc. Natl. Acad. Sci. USA, 2007, 104(23), 9858-9863.
http://dx.doi.org/10.1073/pnas.0607301104 PMID: 17535929

Rix, A.; Laviola, G.; Aloe, L.; di Fausto, V.; Mancinelli, R.; Ceccanti, M. Early exposure to ethanol but not red wine at the same alcohol concentration induces behavioral and brain neurotrophin alterations in young and adult mice. Neurotoxicology, 2009, 30(1), 59-71.
http://dx.doi.org/10.1016/j.neuro.2008.11.009 PMID: 19100286

Tsuji, R.; Fattori, V.; Abe, S.; Costa, L.G.; Kobayashi, K. Effects of postnatal ethanol exposure at different developmental phases on neurotrophic factors and phosphorylated proteins on signal transduction in rat brain. Neurotoxicol. Teratol., 2008, 30(3), 228-236.
http://dx.doi.org/10.1016/j.ntt.2008.01.004 PMID: 18358698

Aloe, L.; Tirassa, P. The effect of long-term alcohol intake on brain NGF-target cells of aged rats. Alcohol. Alcohol, 1992, 27(4), 299-304.
http://dx.doi.org/10.1093/acer.14040 PMID: 18358698

Aloe, L.; Tirassa, P. The effect of long-term alcohol intake on brain NGF-target cells of aged rats. Alcohol. Alcohol, 1992, 27(4), 299-304.
http://dx.doi.org/10.1093/acer.14040 PMID: 18358698

Brace, J.; Venema, L.; Laviola, G.; Aloe, L.; Di Fausto, V.; Mancinelli, R.; Ceccanti, M. Early exposure to ethanol but not red wine at the same alcohol concentration induces behavioral and brain neurotrophin alterations in young and adult mice. Neurotoxicology, 2009, 30(1), 59-71.
http://dx.doi.org/10.1016/j.neuro.2008.11.009 PMID: 19100286
Allen, S.J.; Dawbarn, D. Clinical relevance of the neurotrophins and their receptors. Clin. Sci. (Lond.), 2006, 110(2), 175-191.
http://dx.doi.org/10.1042/CS20050161 PMID: 16411894

Sun, W.; Funakoshi, H.; Nakamura, T. Localization and functional role of hepatocyte growth factor (HGF) and its receptor c-met in the rat developing cerebral cortex. Brain Res. Mol. Brain Res., 2002, 103(1-2), 36-48.
http://dx.doi.org/10.1016/S0169-328X(02)00168-7 PMID: 12106690

Fiore, M.; Mancinelli, R.; Aloe, L.; Laviola, G.; Sornelli, F.; Vitali, M.; Ceccanti, M. Hepatocyte growth factor, vascular endothelial growth factor, glial cell-derived neurotrophic factor and nerve growth factor are differentially affected by early chronic ethanol or red wine intake. Toxicol. Lett., 2009, 188(3), 208-213.
http://dx.doi.org/10.1016/j.toxlet.2009.04.013 PMID: 19397965

Ceccanti, M.; Mancinelli, R.; Tirassa, P.; Laviola, G.; Rossi, S.; Romeo, M.; Fiore, M. Early exposure to ethanol or red wine and long-lasting effects in aged mice: A study on nerve growth factor, brain-derived neurotrophic factor, hepatocyte growth factor, and vascular endothelial growth factor. Neurobiol. Aging, 2012, 33(2), 359-367.
http://dx.doi.org/10.1016/j.neurobiolaging.2010.03.005 PMID: 20382450

Lee, S.; Choi, I.; Kang, S.; Rivier, C. Role of various neurotransmitters in mediating the long-term endocrine consequences of prenatal alcohol exposure. Ann. N. Y. Acad. Sci., 2008, 1144, 176-188.
http://dx.doi.org/10.1196/annals.1418.015 PMID: 19076376

Molnár, I.; Bokk, A. Decreased nerve growth factor levels in hyperthyroid Graves’ ophthalmopathy highlighting the role of neuroprotective factor in autoimmune thyroid diseases. Cytokine, 2006, 35(3-4), 109-114.
http://dx.doi.org/10.1016/j.cyto.2006.08.002 PMID: 17008110

Nakagawara, A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett., 2001, 169(2), 107-114.
http://dx.doi.org/10.1016/S0304-3835(01)00530-4 PMID: 11431098

Ceccanti, M.; De Nicolò, S.; Mancinelli, R.; Chaldakov, G.; Carito, V.; Ceccanti, M.; Laviola, G.; Tirassa, P.; Fiore, M. NGF and BDNF long-term variations in the thyroid, testis and adrenal glands of a mouse model of fetal alcohol spectrum disorders. Ann. Ist. Sper. Sana, 2013, 49(4), 383-390.
http://dx.doi.org/10.4415/ANN-13-04-1124334784 PMID: 24334784

Ichim, G.; Tauszig-Delamasure, S.; Mehlen, P. Neurotrophins and cell death. Exp. Cell Res., 2012, 318(11), 1221-1228.
http://dx.doi.org/10.1016/j.yexcr.2012.03.006 PMID: 22465479